SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California.
A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple double-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc. 旧金山——(商业资讯)——Vir Biotechnology公司(纳斯达克:VIR)今天宣布,首席执行官Marianne De Backer万.Sc., Ph.D., MBA将于1月14日(星期二)下午4:30在加利福尼亚州旧金山举行第43届J.P. Morgan医疗保健会议上发言。
此次演讲的直播网络播出将会在Vir Biotechnology网站的投资者部分的事件与演示中提供,并将在那里存档30天。
关于Vir Biotechnology, Inc.
Vir Biotechnology, Inc.是一家临床阶段的生物制药公司,专注于增强免疫系统以改变生活,发现和开发针对严重传染病和癌症的药物。其临床阶段的投资组合包括针对慢性乙型肝炎δ和慢性乙型肝炎感染的传染病项目,以及多个双盲t细胞刺激剂,涵盖固体肿瘤适应症的验证靶点。Vir Biotechnology还拥有一系列传染病和肿瘤恶性肿瘤的临床前项目组合。Vir Biotechnology定期在其网站上发布可能对投资者重要的信息。
媒体
阿兰·阿特里奇
公司通信-半导体高级副总裁
aattridge@vir.bio
投资者
理查德·莱普基
投资者关系高级董事
rlepke@vir.bio
来源:Vir Biotechnology, Inc.